The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Hi all, not a shareholder, I have a couple of other aim gambles! Interested in this from a personal level. Diagnosed with PC last Feb, had six doxy treatments, developed neutropenia pneumonia and sepsis, all good now. If Iāve read this correctly this will tailor doxy doses to the individual to mitigate risk of neutropenia?
āPolar Capital profits hit by Ā£1.3bn tech outflow
It's been a tougher year for the fund firm after a record-breaking 2021, with performance fees falling sharply in the more challenging conditions.ā
We can take a little heart from that!
The efficacy was compromised because of other simultaneous treatments alongside ifn, basically couldnāt tell which treatment was delivering improvements. This wonāt be the case with Activ 2, so this is not over by a long shot. As a longer term hold, this share will I believe deliver good prospects, hold you nerves if you can.
Pgmcgra, Iām only giving my opinion as to what JVT said. Iāve been in SNG 18 months, would love it to reach the moon. IMO, JVT saying that with effectiveness ( incl cost) of messenger RNA vaccines, the population of treatments will be reduced. Completely take on board cost of hospitalisations etc, Iām personally just lowering my expectation. Still looking for a good return, but some figs quoted on this bb are b******S.
Great progress today, brill finncap note. I want to put something out there that is on my mind. Not being negative so donāt want to be trolled! Iām a LTH in it for the long term. But this is in the back of mind. Interferon is naturally produced. How can Syn adequately patent this. I understand the delivery via nebuliser is key, but surely someone could come up with an alternative delivery process. This is going to be huge, do you think the Chinese (what patent?) would play by the rules? I would welcome genuine feedback on this.